needs to be well calibrated to the target population to ensure optimal treatment. For example, the International Atherosclerosis Society recently published a list of recalibration coefficients to guide adjustment of the Framingham CHD risk score for international use, ranging from 0.36 for China (to avoid overtreatment) to 1.81 for urban India (to avoid undertreatment) (13) . Consequently, for persons with similar risk factor profile, the NNT to prevent 1 ASCVD event is much higher in China than urban India.
The HOPE-3 participants were recruited from countries in which the background population risk and burden of ASCVD are known to differ markedly ( Figure 1) . Further, despite the title of the HOPE-3 paper (1), HOPE-3 did not exclusively enroll "intermediate-risk" persons, although the average risk of the overall study population might have been HOPE-defined risk factor from a population with a low background risk would be substantially below average, where the net benefit of statin therapy might be questionable. In contrast, the net benefit of statin therapy would be higher and initiation of statin therapy more important for a person with multiple HOPE-defined risk factors from a population with a high background risk.
HOPE IN EUROPE
The diversity among the 8 European HOPE-3 countries regarding background population risk, burden of cardiovascular disease, and economic wealth is as extreme as that seen in the whole HOPE-3 study population ( Figure 1) . Among all countries participating in the HOPE-3 trial, $2 and possibly 4 European countries are known to have the highest CHD mortality (Ukraine, Russia, Hungary, and Slovakia), and Ukraine is among the poorest HOPE-3 countries.
In contrast, the Netherlands, Sweden, and United Kingdom belong to the HOPE-3 countries with the lowest CHD mortality and are among the richest countries. The conceptual relationship between NNT to prevent 1 ASCVD event and background population risk in the European HOPE-3 countries is shown in Figure 2 . Guest Editors' Page D E C E M B E R 2 7 , 2 0 1 6 : 2 9 0 3 -6
For a strong statin-modifiable outcome such as CHD, the age-adjusted mortality is more than 10Â higher in Ukraine (337 per 100,000) than the Netherlands (25 per 100,000) (Figure 1 Falk and Mortensen D E C E M B E R 2 7 , 2 0 1 6 : 2 9 0 3 -6
